Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-257
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ABBV-257 is a dual-variable domain immunoglobulin G1 monoclonal antibody designed to selectively neutralize both tumor necrosis factor-alpha (TNF-α) and interleukin-17A (IL-17A). It was developed as a bispecific antibody for the treatment of immune-mediated diseases such as rheumatoid arthritis. The drug acts by inhibiting the activity of both TNF-α and IL-17A, two key cytokines involved in inflammatory pathways. Clinical studies demonstrated that ABBV-257 had dose-proportional pharmacokinetics but also showed a high incidence of antidrug antibodies leading to increased drug clearance and reduced exposure. Due to these immunogenicity concerns, development of ABBV-257 has been discontinued[1][2][4].
- Other names
- Dual-variable domain immunoglobulin 1
02
Targets
IL-17A (Interleukin-17A)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on ABBV-257.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-257.